protocolSection identificationModule nctId: NCT06347003, orgStudyIdInfo id: AROAPOC3-3003, secondaryIdInfos id: 2023-509300-14, type: EUDRACT_NUMBER, briefTitle: Phase 3 Study of Plozasiran in Adults With Severe Hypertriglyceridemia, acronym: SHASTA-3, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2026-07, completionDateStruct date: 2026-10, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Arrowhead Pharmaceuticals, class: INDUSTRY, descriptionModule briefSummary: This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol., conditionsModule conditions: Severe Hypertriglyceridemia, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 405, type: ESTIMATED, armsInterventionsModule interventions name: Plozasiran Injection, interventions name: Placebo, outcomesModule primaryOutcomes measure: Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to Placebo, secondaryOutcomes measure: Percent Change in Fasting Serum TG Levels from Baseline to Month 10 Compared to Placebo, secondaryOutcomes measure: Proportion of Participants Who Achieve Fasting TG Levels of <500 mg/dL (<5.65 mmol/L) at Month 10 and Month 12 Compared to Placebo, secondaryOutcomes measure: Adjudicated Abdominal Clinical Event Rate (Including Emergency Room Visits or Hospitalizations for Abdominal Pain Attributed to Hypertriglyceridemia and Events of Documented Pancreatitis) During the Treatment Period Compared to Placebo at Month 12, secondaryOutcomes measure: Proportion of Participants Who Achieve Fasting TG Levels of <150 mg/dL (<1.69 mmol/L) at Month 10 and Month 12 Compared to Placebo, secondaryOutcomes measure: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) Over Time through Month 12 as Compared to Placebo, secondaryOutcomes measure: Incidence Rates of New-Onset Diabetes Mellitus (NODM) Throughout the Course of Treatment, secondaryOutcomes measure: Incidence Rates of Impaired Glucose Tolerance Throughout the Course of Treatment, secondaryOutcomes measure: Incidence Rates of Worsening of Existing Diabetes Throughout the Course of Treatment, secondaryOutcomes measure: Change from Baseline in Hemoglobin A1c (HbA1c) During the Treatment Period Compared to Placebo, secondaryOutcomes measure: Change from Baseline in Fasting Blood Glucose During the Treatment Period Compared to Placebo, secondaryOutcomes measure: Change from Baseline in C-peptide During the Treatment Period Compared to Placebo, secondaryOutcomes measure: Change from Baseline in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) During the Treatment Period Compared to Placebo, secondaryOutcomes measure: Incidence Rates of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) Associated with Worsening Glycemic Control During the Treatment Period Compared to Placebo, secondaryOutcomes measure: Initiation of New Medication for Hyperglycemia Among Study Participants Not Known to Have Pre-existing Diabetes Mellitus During the Treatment Period Compared to Placebo, secondaryOutcomes measure: Adjudicated Major Adverse Cardiovascular Events (MACE) Rates During the Treatment Period Compared to Placebo, secondaryOutcomes measure: Incidence of Anti-drug Antibodies (ADA) to Plozasiran in Participants Receiving Plozasiran Over Time Through Month 12, secondaryOutcomes measure: Titers of Anti-drug Antibodies (ADA) to Plozasiran in Participants Receiving Plozasiran Over Time Through Month 12, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False